CB-13 (CRA13, SAB-378) is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies, and has progressed to preliminary human trials.
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dct:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
H |
|
IUPAC name |
|
O |
|
PubChem |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
UNII |
|
verifiedrevid |
|
width |
|
has abstract |
|
legal CA |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
ChEMBL |
|
FDA UNII code |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of |